Sublocade

DRUG7 trials

Conditions

BuprenorphineIncarcerationMedications for Opioid Use DisorderModerate to Severe Opioid Use DisorderOpioid Use DisorderOpioid Use Disorder, ModerateOpioid Use Disorder, SevereOpioid-use Disorder

Phase 1

An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder

CompletedNCT03861338

New York State Psychiatric InstituteOpioid-use Disorder

Start: 2019-03-01End: 2020-02-28Updated: 2021-03-09

Phase 2

INDV-6001 Multiple-Dose Pharmacokinetic Study

CompletedNCT06576843

Indivior Inc.Moderate to Severe Opioid Use Disorder

Start: 2024-09-17End: 2026-01-21Updated: 2026-03-16

Phase 3

Virginia Opioid Overdose Treatment InitiatVE

TerminatedNCT03818399

Virginia Commonwealth UniversityOpioid Use Disorder

Start: 2019-01-04End: 2021-02-24Updated: 2022-05-05

Virginia Opioid Treatment-Emergency Department

WithdrawnNCT04523792

Virginia Commonwealth UniversityOpioid Use Disorder

Start: 2021-01-01End: 2021-12-31Updated: 2021-02-12

Phase 4

SUBLOCADE Rapid Initiation Study

CompletedNCT03993392

Indivior Inc.Opioid-use Disorder

Start: 2019-08-29End: 2019-12-26Updated: 2025-03-25

SUBLOCADE Rapid Initiation Extension Study

CompletedNCT04060654

Indivior Inc.Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe

Start: 2019-10-21End: 2020-05-15Updated: 2025-03-25

Injectable Buprenorphine in Prison: a Preference Trial

Not yet recruitingNCT06880718

LifespanBuprenorphine, Incarceration, Medications for Opioid Use Disorder +1

Start: 2025-06-30End: 2027-06-30Target: 60Updated: 2025-03-20

Related Papers

Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection

The American Journal of Drug and Alcohol Abuse2022-08-2414 citations